TB-500 and tissue repair
TB-500 is a short synthetic peptide modeled on part of thymosin beta-4, a protein the body makes that is involved in cell movement and the formation of new blood vessels.
The mechanism researchers propose
TB-500 is a seven-amino-acid fragment that matches positions 17 to 23 of the 43-amino-acid thymosin beta-4 protein. The idea is that it can reproduce some of the protein’s activity, including helping cells migrate and supporting new vessel growth around injured tissue.
Most of the supporting data come from animal and cell studies of the full thymosin beta-4 protein, not from TB-500. A 2024 study reported that TB-500 itself did not improve wound healing, while one of its breakdown products did.
The BPC-157 peptide has a larger, though still mostly animal, evidence base.
Human evidence
The few human trials reported are small phase 2 studies of topical products for skin wounds, not tendon or muscle injury, and no phase 3 trial exists. Large or long-term safety studies are lacking.
Product quality is a separate risk. Unregulated TB-500 has been reported to contain endotoxins, truncated sequences and metals. Athletes should know it is prohibited at all times under WADA rules.
Labs track safety, not proof of repair, as explained under recovery biomarkers. Our guide describes what independent labs found in gray-market peptides.
Strength of the evidence
- Early lab and animal research
- Small human studies
- Controlled human trials
- Approved for this use
Early lab and animal research. Small topical human studies in skin wounds only. None in tendon, ligament or muscle.
Regulatory status
- Not FDA-approved for any use.
- Placed in FDA Category 2 in late 2023. In April 2026 the FDA announced it would remove it from that list after the nomination was withdrawn. Removal does not make it eligible for compounding.
- On July 23, 2026, an FDA advisory committee voted 8 to 6 to recommend adding it to the 503A bulks list. The vote is not binding and formal rulemaking is required.
Current as of October 28, 2026. Status is changing. Confirm with the FDA before relying on it. Sources are listed in the safety guide.
About the clinical team behind this page
Dr. Penni Russo-Going is a physician trained in family medicine and surgery, with a focus on trauma surgery. At Nova she advises on post-surgical tendon and joint recovery, soft-tissue trauma and the systemic and metabolic factors that affect healing, and she reviews content on those topics.
Dr. Arnaldo Manuel Mora is Medical Director and leads clinical governance at Nova. His background is in internal and occupational medicine. He oversees diagnostic intake, baseline laboratory review and the safety standards that apply before any prescription therapy, including pharmacy sourcing and contraindication screening as described in our safety guide.
Medical disclaimer: The information on this site is for education and does not replace a consultation, diagnosis or treatment. Peptides are prescription-only at Nova, are prescribed only after an in-person physician evaluation, and are not FDA-approved for orthopedic use. Full credentials are on our physicians and clinical governance page.
Keep reading
Individual results vary and no outcome is guaranteed. Peptides discussed on this site are not FDA-approved for orthopedic use, and a physician decides after an in-person evaluation whether any is appropriate.